Spesolimab for generalized pustular psoriasis: A prospective study with a 6-month-follow-up. Journal Abstract - Guideline Central

Spesolimab for generalized pustular psoriasis: A prospective study with a 6-month-follow-up.

Published: 2026 Apr 18

Authors

, , , , , , , , , , , ,

Abstract

Generalized pustular psoriasis (GPP) is a rare, life-threatening skin disease. Spesolimab, an anti-IL-36R monoclonal antibody, has shown efficacy in clinical trials, yet real-world data remain limited.

Source

Clinical and experimental dermatology

Publication Type

Journal Article

Language

English

PubMed ID

41999186

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.